Threshold Pharma, ATOMIC Initiate First Phase 2 Trial of TH-4000 in Patients with Advanced EGFR-Mutant, T790M-NSCLC
August 11, 2015 at 07:06 AM EDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology ...